Ibaraki, Japan

Hiroki Asakura

This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Astex Therapeutics Limited. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroki Asakura: Innovator in Chemical Derivatives

Introduction

Hiroki Asakura is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of chemistry, particularly in the development of novel chemical compounds. His work has led to the creation of a patent that showcases his innovative approach to chemical derivatives.

Latest Patents

Hiroki Asakura holds a patent for "4-Aminobut-2-enamide Derivatives and Salt Thereof." This patent represents his research and development efforts in creating new chemical entities that may have various applications in pharmaceuticals and other industries. He has 1 patent to his name, reflecting his commitment to advancing chemical science.

Career Highlights

Asakura is currently employed at Astex Therapeutics Limited, a company known for its focus on innovative drug discovery and development. His role at Astex Therapeutics allows him to collaborate with other talented scientists and contribute to groundbreaking research in the pharmaceutical sector.

Collaborations

Throughout his career, Hiroki has worked alongside esteemed colleagues such as Kazuaki Shibata and Yuichi Kawai. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Hiroki Asakura is a dedicated inventor whose work in chemical derivatives has the potential to impact various industries. His contributions to Astex Therapeutics and his patent achievements highlight his role as a key player in the field of chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…